Cannabis Is Leaving The Dispensary. Washington Holds The Key To What’s Next
Cannabis is moving from dispensary counters into mainstream retail coolers. The sector's next leg depends on whether Washington lets that shift continue.
Congress delayed new hemp restrictions this week, giving THC product makers one more month to defend a fast-growing category.
Drinks changed the customer
THC beverages have become the clearest example of cannabis leaving old stoner branding behind. Measured US retail sales reached $239M in the 52 weeks through April, according to NielsenIQ data cited by CNBC.
The category also has a different pitch than traditional cannabis. Lower-dose cans aim to feel closer to an after-work drink than a high-potency dispensary product.
Cann CEO Jake Bullock said the brand started with a simple question about social use.
"How do we communicate that this is social."
Jake Bullock, Cann
Cann has leaned into pastel packaging and low-dose drinks instead of leaf-heavy visuals. The company generated nearly $40M in revenue last year.
The consumer data supports that broader shift. Gallup found 17% of US adults reported smoking marijuana, while 15% reported using edibles in its latest survey.
Rescheduling lifts operators
Cannabis has a second policy catalyst beyond hemp drinks. The Justice Department said recently that FDA-approved marijuana products and state-legal products would move from Schedule 1 to Schedule 3.
That matters because Schedule 3 can ease research limits and federal tax pressure. The biggest direct benefit is relief from 280E, the tax rule that blocks cannabis businesses from deducting normal expenses.
Public companies tied to cannabis have reacted to the shift. Jazz Pharmaceuticals was the best one-year performer in NerdWallet's screened list, with a 97.43% return.
Cronos Group was up 29.42% over the same period. Innovative Industrial Properties was up 0.15%, showing how uneven cannabis-linked exposure remains.
The investable universe is still narrow and risky. Many cannabis companies remain small, and several US-traded names are Canadian operators with different reporting and market risks.
Politics keeps exposure uneven
The near-term trigger is federal policy. The House passed a stopgap spending measure that delayed new restrictions on hemp-derived THC products from Nov. 12 to Dec. 11.
That delay keeps products on shelves for now. It also leaves distributors unsure about restocking inventory before Congress decides whether to ban or regulate the category.
Bullock said Cann is seeing record sales to retailers. He also said wholesalers have pulled back because they do not want unsold product if rules change.
Crescent Canna CEO Joe Gerrity said his company has already laid off half its employees. He blamed congressional uncertainty for forcing hard decisions before the deadline.
"Nobody wants to get left holding the bag."
Joe Gerrity, Crescent Canna
The sector wants rules rather than a ban. Bullock told CNBC the beverage industry's goal is regulation similar to alcohol, not an open-ended loophole.
Cannabis reform has also become a midterm issue. Massachusetts and Idaho will vote on ballot measures in November, while candidates in Kansas and Iowa are debating legalization.
National support is not one-way. Gallup polling cited by CNBC showed 64% of US adults think marijuana should be legal, down from 70% in 2023.
Pure-play operators offer the highest policy sensitivity. Ancillary names and pharmaceutical-linked companies can reduce direct exposure to plant-touching business risk. Cannabis is still a speculative trade, but Washington is finally giving investors more ways to pick winners.